Medicalisation, smoking and e-cigarettes: Evidence and implications

Tobacco Control

Volumn 26, Issue e2, 2017, Pages E134-E139

  Morphett, Kylie ^a   Carter, Adrian ^b   Hall, Wayne ^a,c   Gartner, Coral ^a,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE;

CHRONIC DISEASE; ELECTRONIC CIGARETTE; HUMAN; MEDICALIZATION; PROCEDURES; PSYCHOLOGY; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE; TOBACCO INDUSTRY;

CHRONIC DISEASE; ELECTRONIC NICOTINE DELIVERY SYSTEMS; HUMANS; MEDICALIZATION; NICOTINE; SMOKING; SMOKING CESSATION; TOBACCO INDUSTRY; TOBACCO USE DISORDER;

EID: 85001777496     PISSN: 09644563     EISSN: 14683318     Source Type: Journal    
DOI: 10.1136/tobaccocontrol-2016-053348     Document Type: Article

References (93)

1. Chapman S, MacKenzie R. The global research neglect of unassisted smoking cessation: causes and consequences. PLoS Med 2010;7:e1000216.
2. Dingel MJ, Karkazis K, Koenig BA. Framing nicotine addiction as a “disease of the brain”: social and ethical consequences. Soc Sci Q 2011;92:1363–88.
3. Caron L, Karkazis K, Raffin TA, et al. Nicotine addiction through a neurogenomic prism: ethics, public health, and smoking. Nicotine Tob Res 2005;7: 181–97.
4. Conrad P, Schneider JW. Deviance and medicalization: from badness to sickness. 2nd edn Philadelphia: Temple University Press, 1992.
5. Zola IK. Medicine as an institution of social control. Sociol Rev 1972;20:487–504.
6. Clarke AE, Shim JK, Mamo L, et al. Biomedicalization: technoscientific transformations of health, illness, and US biomedicine. Am Sociol Rev 2003;68:161–94.
7. Conrad P. The shifting engines of medicalization. J Health Soc Behav 2005;46:3–14.
8. Berridge V. Two tales of addiction; opium and nicotine. Hum Psychopharm Clin 1997;12:S45–52.
9. Tyrrell I. Before the surgeon-general’s report: public discourse in Australia over tobacco addiction to 1964. Aust J Politics Hist 1998;44:177.
10. US Surgeon General. The health consequences of smoking: nicotine addiction. Washington: U.S. Department of Health and Human Services, 1988.
11. Elam MJ. Nicorette reborn? E-cigarettes in light of the history of nicotine replacement technology. Int J Drug Policy 2015;26:536–42.
12. Hirshbein LD. Politics, profit, and psychiatric diagnosis: a case study of tobacco use disorder. Am J Public Health 2014;104:2076–84.
13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders—text revision (DSM-IV-TR). Washingon DC: American Psychiatric Association, 2000.
14. Hartmann-Boyce J, Stead LF, Cahill K, et al. Efficacy of interventions to combat tobacco addiction: Cochrane update of 2012 reviews. Addiction 2013;108:1711–21.
15. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008;(1):CD000146.
16. World Health Organisation. 16th WHO model list of essential medicines. WHO, 2015.
17. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012;(4):CD006103.
18. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2010;(3):CD000031.
19. Beard E, Shahab L, Cummings DM, et al. New pharmacological agents to aid smoking cessation and tobacco harm reduction: what has been investigated, and what is in the pipeline? CNS Drugs 2016;30:1–33.
20. Cooper J, Borland R, Yong HH. Australian smokers increasingly use help to quit, but number of attempts remains stable: findings from the International Tobacco Control Study 2002–09. Aust N Z J Public Health 2011;35:368–76.
21. West R, Fidler J. Smoking and smoking cessation in England 2010. London: Smoking in England, 2011. http://www.smokinginengland.info/reports/
22. Balmford J, Borland R, Hammond D, et al. Adherence to and reasons for premature discontinuation from stop-smoking medications: data from the ITC four-country survey. Nicotine Tob Res 2011;13:94–102.
23. Fucito LM, Toll BA, Salovey P, et al. Beliefs and attitudes about bupropion: implications for medication adherence and smoking cessation treatment. Psychol Addict Behav 2009;23:373–9.
24. Shelley D, Tseng TY, Gonzalez M, et al. Correlates of adherence to varenicline among HIV+ smokers. Nicotine Tob Res 2015;17:968–74.
25. Centers for Disease Control and Prevention. Quitting smoking among adults—United States, 2001–2010. MMWR Morb Mortal Wkly Rep 2011;60:1513–22.
26. Reid JL, Hammond D, Rynard VL, et al. Tobacco use in Canada: patterns and trends. Propel Centre for Population Health Impact, University of Waterloo, 2015.
27. Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Rockville, Maryland: U.S. Department of Health and Human Services, 2008.
28. National Institute for Health and Clinical Excellence. Smoking cessation services quick reference guide. London: National Health Service, 2008.
29. Zwar NA, Richmond R, Borland R, et al. Supporting smoking cessation: a guide for health professionals (Updated July 2014). The Royal Australian College of General Practitioners, 2014.
30. Aveyard P, Raw M. Improving smoking cessation approaches at the individual level. Tob Control 2012;21:252–7.
31. Richter KP, Ellerbeck EF. It’s time to change the default for tobacco treatment. Addiction 2014;110:381–6.
32. Fabbri LM. Smoking, not COPD, as the disease. N Engl J Med 2016;374:1885–6.
33. Leshner AI. Addiction is a brain disease, and it matters. Science 1997;278:45–7.
34. Volkow ND, Li T-K. Drug addiction: the neurobiology of behaviour gone awry. Nat Rev Neurosci 2004;5:963–70.
35. White W. Slaying the dragon: the history of addiction treatment and recovery in America. Bloomington, IL: Chestnut Health Systems/Lighthouse Institute, 1998.
36. Prochaska JJ, Benowitz NL. The past, present, and future of nicotine addiction therapy. Annu Rev Med 2016;67:467–86.
37. Dackis C, O’Brien C. Neurobiology of addiction: treatment and public policy ramifications. Nat Neurosci 2005;8:1431–6.
38. Amiaz R, Levy D, Vainiger D, et al. Repeated high-frequency transcranial magnetic stimulation over the dorsolateral prefrontal cortex reduces cigarette craving and consumption. Addiction 2009;104:653–60.
39. Rose J, McClernon FJ, Froeliger B, et al. Repetitive transcranial magnetic stimulation of the superior frontal gyrus modulates craving for cigarettes. Biol Psychiatry 2011;70:794–9.
40. Addicott MA, Sweitzer MM, Froeliger B, et al. Increased functional connectivity in an insula-based network is associated with improved smoking cessation outcomes. Neuropsychopharmacology 2015;40:2648–56.
41. Loughead J, Wileyto EP, Ruparel K, et al. Working memory-related neural activity predicts future smoking relapse. Neuropsychopharmacology 2015;40:1311–20.
42. McClure JB, Swan GE, St. et al. Pharmacogenetic smoking cessation intervention in a healthcare setting: a pilot feasibility study. Nicotine Tob Res 2013;15:518–26.
43. Etter JF, Burri M, Stapleton J. The impact of pharmaceutical company funding on results of randomized trials of nicotine replacement therapy for smoking cessation: a meta-analysis. Addiction 2007;102:815–22.
44. Parrott S, Godfrey C. ABC of smoking cessation: economics of smoking cessation. Br Med J 2004;328:947–9.
45. Britton J. In defence of helping people to stop smoking. Lancet 2009;373:703–5.
46. Zhu S-H, Lee M, Zhuang YL, et al. Interventions to increase smoking cessation at the population level: how much progress has been made in the last two decades? Tob Control 2012;21:110–18.
47. Gundle KR, Dingel MJ, Koenig BA. ‘To prove this is the industry’s best hope’: big tobacco’s support of research on the genetics of nicotine addiction. Addiction 2010;105:974–83.
48. Gartner C, Carter A, Partridge B. What are the public policy implications of a neurobiological view of addiction? Addiction 2012;107:1199–200.
49. Kvaale EP, Gottdiener WH, Haslam N. Biogenetic explanations and stigma: a meta-analytic review of associations among laypeople. Soc Sci Med 2013;96:95–103.
50. Pescosolido BA, Martin JK, Long JS, et al. “A disease like any other”? A decade of change in public reactions to schizophrenia, depression, and alcohol dependence. Am J Psychiatry 2010;167:1321–30.
51. Elam MJ. How the brain disease paradigm remoralizes addictive behaviour. Science as Culture 2015;24:46–64.
52. World Health Organisation. WHO framework convention on tobacco control. Switzerland: WHO, 2005.
53. Kishore SP, Bitton A, Cravioto A, et al. Enabling access to new WHO essential medicines: the case for nicotine replacement therapies. Globalization Health 2010;6:1–6.
54. Keane H. What’s wrong with addiction? South Carlton, Vic: Melbourne University Press, 2002.
55. Mayo Clinic. Nicotine Dependence Centre in Minnesota. Secondary Nicotine Dependence Centre in Minnesota 2015. http://www.mayoclinic.org/ departments-centers/nicotine-dependence-center/minnesota/services/ residential-treatment-program
56. Hammond D, McDonald PW, Fong GT, et al. Do smokers know how to quit? Knowledge and perceived effectiveness of cessation assistance as predictors of cessation behavior. Addiction 2004;99:1042–8.
57. Shiffman S, Ferguson SG, Rohay J, et al. Perceived safety and efficacy of nicotine replacement therapies among US smokers and ex-smokers: relationship with use and compliance. Addiction 2008;103:1371–8.
58. Willems RA, Willemsen MC, Nagelhout GE, et al. Understanding smokers’ motivations to use evidence-based smoking cessation aids. Nicotine Tob Res 2013;15:167–76.
59. Vogt F, Hall S, Marteau TM. Understanding why smokers do not want to use nicotine dependence medications to stop smoking: qualitative and quantitative studies. Nicotine Tob Res 2008;10:1405–13.
60. Smith AL, Carter SM, Chapman S, et al. Why do smokers try to quit without medication or counselling? A qualitative study with ex-smokers. BMJ Open 2015;5: e007301.
61. Bansal MA, Cummings KM, Hyland A, et al. Stop-smoking medications: who uses them, who misuses them, and who is misinformed about them? Nicotine Tob Res 2004;6(Suppl 3):S303–S10.
62. Cummings KM, Hyland A, Giovino GA, et al. Are smokers adequately informed about the health risks of smoking and medicinal nicotine? Nicotine Tob Res 2004;6 (Suppl 3):S333–S40.
63. Mooney ME, Leventhal AM, Hatsukami DK. Attitudes and knowledge about nicotine and nicotine replacement therapy. Nicotine Tob Res 2006;8:435–46.
64. Chapman S. Is nicotine really as safe as e-cigarette supporters make out?. Secondary is nicotine really as safe as e-cigarette supporters make out? 2016. https://theconversation.com/ is-nicotine-really-as-safe-as-e-cigarette-supporters-make-out-61007
65. Royal College of Physicians. Nicotine without smoke: tobacco harm reduction. RCP, 2016.
66. Johnson SE. What the public knows and believes about nicotine: insights from recent quantitative and qualitative evidence. SRNT Conference. Chicago. 2 March 2016.
67. Morphett K, Partridge B, Gartner C, et al. Why Don’t smokers want help to quit? A qualitative study of smokers’ attitudes towards assisted vs. unassisted quitting. Int J Environ Res Public Health 2015;12:6591.
68. Katainen A. Challenging the imperative of health? Smoking and justifications of risk-taking. Critical Public Health 2006;16:295–305.
69. Kayser JW, Semenic S. Smoking motives, quitting motives, and opinions about smoking cessation support among expectant or new fathers. J Addict Nurs 2013;24:149–57.
70. Uppal N, Shahab L, Britton J, et al. The forgotten smoker: a qualitative study of attitudes towards smoking, quitting, and tobacco control policies among continuing smokers. BMC Public Health 2013;13:432.
71. Wiltshire S, Bancroft A, Parry O, et al. ‘I came back here and started smoking again’: perceptions and experiences of quitting among disadvantaged smokers. Health Educ Res 2003;18:292–303.
72. Hughes JR. Smokers’ beliefs about the inability to stop smoking. Addict Behav 2009;34:1005–9.
73. Abrams DB. Promise and peril of e-cigarettes: can disruptive technology make cigarettes obsolete? JAMA 2014;311:135–6.
74. Fairchild AL, Bayer R, Colgrove J. The renormalization of smoking? E-Cigarettes and the tobacco “Endgame”. N Engl J Med 2014;370:293–5.
75. Bell K, Keane H. Nicotine control: E-cigarettes, smoking and addiction. Int J Drug Policy 2012;23:242–7.
76. Rooke C, Cunningham-Burley S, Amos A. Smokers’ and ex-smokers’ understanding of electronic cigarettes: a qualitative study. Tob Control 2015;25:e60–6.
77. British American Tobacco. E-cigarettes and other Next Generation products. Secondary E-cigarettes and other Next Generation products 2016. http://www.bat.com/ecigarettes
78. McEwan A, McRobbie H. Electronic cigarettes: a briefing for stop smoking services. National Centre for Smoking Cessation and Training, 2016.
79. Jeffrey D. FDA loses appeal, can’t regulate e-cigarettes as drug. Bloomberg 2010. http://www.bloomberg.com/news/articles/2010-12-07/fda-can-t-regulate-electronic-cigarettes-as-drug-u-s-appeals-court-rules
80. Wheeler L. Company files first lawsuit against the FDA’s e-cigarette rule. The Hill 2016. http://thehill.com/regulation/court-battles/279413-company-files-lawsuit-challenging-fdas-new-tobacco-rule
81. New Zealand Ministry of Health. Media release: E-cigarette consultation opens. 2016. http://www.health.govt.nz/news-media/media-releases/ e-cigarette-consultation-opens
82. Government of Canada. Media release: Government of Canada announces next steps in tobacco control. 2016. http://www.health.govt.nz/news-media/media-releases/e-cigarette-consultation-opens
83. Australian Government Therapeutic Goods Administration. Consultation: proposed amendments to the Poisons Standard—ACMS meeting, 2016. https://www.tga.gov.au/consultation-invitation/consultation-proposed-amendments-poisons-standardacms-meeting-november-2016
84. Beard E, West R, Michie S, et al. Association between electronic cigarette use and changes in quit attempts, success of quit attempts, use of smoking cessation pharmacotherapy, and use of stop smoking services in England: time series analysis of population trends. BMJ 2016;354:i4645.
85. West R, Beard E, Brown J. Trends in electronic cigarette use in England. Smoking Toolkit Study, 2016. http://www.smokinginengland.info/sts-documents/
86. Zhuang YL, Cummins SE, Y Sun J, et al. Long-term e-cigarette use and smoking cessation: a longitudinal study with US population. Tob Control 2016;25(Suppl 1): i90–5.
87. Fraser D, Weier M, Keane H, et al. Vapers’ perspectives on electronic cigarette regulation in Australia. Int J Drug Policy 2015;26:589–94.
88. Adkison SE, O’Connor RJ, Bansal-Travers M, et al. Electronic Nicotine Delivery Systems: International Tobacco Control Four-Country Survey. Am J Prev Med 2013;44:207–15.
89. Borland R. Paying more attention to the ‘elephant in the room’. Tob Control 2016; .
90. Hatsukami DK, Zaatari G, Donny E. The case for the WHO Advisory Note, Global Nicotine Reduction Strategy. Tob Control 2016;.
91. Kozlowski LT.Cigarette prohibition and the need for more prior testing of the WHO TobReg’s global nicotine-reduction strategy. Tob Control 2016;.
92. Rooke C. Harm reduction and the medicalisation of tobacco use. Sociol Health Illn 2012;35:361–76.
93. Britton J. Electronic cigarettes and smoking cessation in England. BMJ 2016;354: i4819.